Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Declines By 21.4%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 7,700 shares, a drop of 21.4% from the January 15th total of 9,800 shares. Based on an average trading volume of 19,200 shares, the short-interest ratio is presently 0.4 days. Approximately 0.6% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Xenetic Biosciences Price Performance

Xenetic Biosciences stock opened at $4.11 on Friday. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20. The stock has a market cap of $6.33 million, a PE ratio of -1.54 and a beta of 2.23. The stock’s fifty day moving average is $4.15 and its two-hundred day moving average is $4.00.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The business had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.75 million. On average, research analysts expect that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation purchased a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.